Press Releases

Nanomedical Diagnostics CTO Brett Goldsmith to Speak at David Myszka’s SensorCon 2018 Conference

San Diego | September 18, 2018

Dr. Goldsmith will share experiments showcasing characterization of MYC oncoprotein, Zika virus, G-protein-coupled receptors, and aptamers with Agile R100, a versatile Field Effect Biosensing system.

Nanomedical Diagnostics Agile R100 Graphene Biosensor Characterizes Difficult-to-Study MYC Oncoprotein for Cancer Research

San Diego | August 7, 2018

Using data gathered by Agile R100, a kinetic binding assay system, scientists from Dr. Kim Janda’s laboratory at the Scripps Research Institute developed a new series of compounds with the potential to down-regulate the transcriptional activities of MYC.

Nanomedical Diagnostics Launches New Graphene Biosensor for Validating Primary Screen Hits During Early Stage Drug Discovery

San Diego | July 10, 2018

False positives are common when using labeled biochemical assays to measure high-concentration interactions. SCOOH Agile biosensors present a possible solution.

Nanomedical Diagnostics Releases Report on Field Effect Biosensing vs. Isothermal Titration Calorimetry

San Diego | June 5, 2018

ITC, commonly used to analyze small molecule and protein interactions, consumes large amounts of sample and has low throughput. Nanomedical Diagnostics presents a possible alternative.

Nanomedical Diagnostics Releases Report on Affinity Ranking for Hit Validation

San Diego | May 8, 2018

Labels can get in the way of accurate ranking for tight-binding interactions. Nanomedical Diagnostics presents biochemists a possible solution.

Nanomedical Diagnostics Launches New Graphene Biosensor for Label-Free Characterization of Antibodies, Peptides, and Small Molecule Compounds 

San Diego | March 27, 2018

NH2 Agile biosensors provide flexible kinetic characterization for drug discovery research.

Nanomedical Diagnostics Launches New Graphene Biosensor for Label-Free Characterization of Integral Membrane Proteins

San Diego | February 27, 2018

FLEX Agile biosensors provide kinetic binding analysis for GPCRs, ion channels, enzymes, and receptors.

Nanomedical Diagnostics Founder and CTO Brett Goldsmith to Speak at Society for Laboratory Automation and Screening 2018 Conference

San Diego | January 30, 2018

Dr. Goldsmith will share the role the company’s graphene biosensor plays in increasing the speed and efficiency of small molecule drug discovery.

Joe Keegan, Former CEO of Octet-manufacturer FortéBio, Appointed Executive Chairman of Nanomedical Diagnostics

San Diego | January 9, 2018

Dr. Keegan to spearhead fundraising, product development, and sales strategy as company begins development of high-throughput kinetic characterization system.

Nanomedical Diagnostics Launches New Getting Started Kit for Agile R100 Label-free Personal Assay System

San Diego | December 5, 2017

The GSK enables a new user to learn how to characterize small molecules using the breakthrough kinetic binding platform in under four hours.

New Patent Issued to Nanomedical Diagnostics for Use of Graphene Biosensors with DNA Probes to Identify DNA Sequences for Precision Medicine

San Diego | October 17, 2017

Ability to apply the highly sensitive and affordable technology for non-invasive tumor-specific DNA detection brings the holy grail of early cancer detection one step closer.

New Portable, Cost-effective Agile R100 Detects Zika Viral Protein with High Sensitivity and Specificity

San Diego | September 12, 2017

Label-free Agile R100, by Nanomedical Diagnostics, may enable detection of Zika virus with low false positives. Antibodies developed by the Centers for Disease Control (CDC) were used to directly detect the viral protein Zika NS1 at clinically relevant levels of sensitivity.

Nanomedical Diagnostics Launches New Agile Biosensor to Accelerate Label-free Drug Development

San Diego | August 15, 2017

NHS Agile biosensors provide kinetic characterization of drug compounds and biopharmaceuticals with unprecedented ease and reliability.

Nanomedical Diagnostics Launches New Biosensor for Label-free Kinetic Binding Analysis of Proteins

San Diego | July 18, 2017

NTA biosensors let drug discovery researchers characterize proteins faster, easier, and more reliably.

Nanomedical Diagnostics Benchtop Kinetic Binding Platform Displays Unprecedented High Signal-to-Noise Ratio in Comparison Study Showcased in MRS Advances

San Diego | June 20, 2017

Label-free Agile R100 demonstrates detection of Zika antigen at 10 times lower concentration than Octet.

Nanomedical Diagnostics Issued Key Patent for Agile R100, a Graphene Biosensor for Drug Discovery

San Diego | May 9, 2017

Quantitative, label-free characterization system covered by patent enables sensitive kinetic binding and affinity data for life science research.

Nanomedical Diagnostics VP Production To Speak at Materials Research Society Spring Meeting

San Diego | April 11, 2017

Dr. Mitchell Lerner will share details about the fabrication process behind the world’s first mass-manufactured graphene biosensor, Agile R100.

Nanomedical Diagnostics Announces Partnership with Rogue Valley Microdevices, Delivering World’s First Successful High-Volume Manufacturing for Graphene Biosensors

San Diego | March 8, 2017

Agile R100, a kinetic binding platform created by the cost-effective, high-throughput fabrication process, gives pharmaceutical companies access to a novel label-free biophysical characterization tool.

Nanomedical Diagnostics to Present Field Effect Biosensing for Fragment-Based Drug Discovery at SLAS 2017

San Diego | January 24, 2017

Novel FEB technology provides high-quality kinetic binding and affinity data to accurately identify hits.

Nanomedical Diagnostics Electronic Label-Free Assay Supports Positive Cooperativity in Study Published in Nature

San Diego | December 1, 2016

Kinetic binding data generated by the easy-to-use Agile R100 system supports a new pathway for treatment of diseases.

Nanomedical Diagnostics CEO and CTO to Introduce Electronic Label-Free Assay Based on Field Effect Biosensing Technology at IDTechEx Show

San Diego | November 10, 2016

Ross Bundy and Dr. Brett Goldsmith will share how Agile R100 provides small therapeutics companies access to the same data available to large pharma.

Joe Keegan, Former CEO of Octet-manufacturer ForteBio, joins Nanomedical Diagnostics Board of Directors

San Diego | November 1, 2016

Dr. Keegan to provide expertise in the label-free detection market as the company expands sales of Agile R100, its benchtop biosensor assay for lead optimization.

Nanomedical Diagnostics Announces Peer-Reviewed Publication Demonstrating High Sensitivity and Selectivity With the Agile R100 Label-Free Electronic Assay

San Diego | October 11, 2016

Co-authored by scientists from UCSD and UCI, the publication highlights enzyme, antibody, and insulin experiments that showcase Agile R100’s ability to exceed current protein characterization methods.

Nanomedical Diagnostics Founder and CTO to Highlight Launch of World’s First Commercialized Graphene Biosensor at the Graphene World Summit

San Diego | September 15, 2016

Leading nanotechnology expert Dr. Brett Goldsmith will share graphene’s key role in Agile R100, an all-electronic, label-free binding assay.

Nanomedical Diagnostics’ Novel Agile Graphene Biosensor Advances Kinase Research for the Development of Therapeutic Pharmaceuticals

San Diego | July 20, 2016

Study published in the Journal of the American Chemical Society demonstrates previously unattainable measurements for kinase drug discovery.